Expression and Correlation Analysis of Clinical Pathological Characteristics of Vascular Endothelial Growth Factor, Matrix Metalloproteinases and Microvessel Density in Lung Cancer with Bone Metastasis

2019 ◽  
Vol 9 (9) ◽  
pp. 1232-1237
Author(s):  
Xuefei Qi ◽  
Hong Liu ◽  
Ruiyun Liu ◽  
Lixin Sun ◽  
Xinjuan Yu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Vascular Endothelial ◽  
Factor Matrix ◽  
Lung Cancer Patients ◽  
Tumor Group ◽  
Endothelial Growth Factor

Lung cancer is a common malignant tumor in clinic and easy to have bone metastases. Vascular endothelial growth factor (VEGF) is an angiogenic factor. Matrix metalloproteinases (MMPs) is associated with invasion and metastases. This study was to detect VEGF, microvessel density (MVD), MMP-2 and MMP-9 (MMP-2/9) levels in the serum and tissues of lung cancer patients with bone metastases to analyze the relaitonship between these changes and lung cancer with bone metastases. 60 patients with metastatic tumor of lung cancer were selected as experimental group, primary malignant tumor of bone and benign osteoma were regarded as control group, the contents of VEGF, MMP-2/9 in blood and tissues were analyzed by ELISA and IHC, respectively. VEGF, MVD, MMP-2/9 levels in serum and tissues of lung cancer bone metastasis group were significantly higher than that of primary bone tumor group and benign bone tumor group and their changes were significantly associated with pathological types of lung cancer, numbers and sizes of primary foci, numbers of bone metastases, other organ metastases and whether or not receiving radiotherapy and chemotherapy (P < 0.05). In conclusion, the level of VEGF, MVD, MMP-2/9 is significantly elevated in lung cancer patients with bone metastases, suggesting that these molecules might be involved in the pathogenesis of lung cancer with bone metastases.

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

2010 ◽  
Vol 28 (4) ◽  
pp. 393-398 ◽  
Author(s):  
Enrique Carrillo-de Santa Pau ◽  
Fernando Carrillo Arias ◽  
Enrique Caso Pelaez ◽  
Ignacio Muguruza Trueba ◽  
Ignacio Sánchez Hernández ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Lung Cancer Patients ◽  
Early Stages ◽  
Endothelial Growth Factor

Efficacy and safety of apatinib plus docetaxel for non-squamous non-small cell lung cancer with bone metastases.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21741-e21741
Author(s):  
Aimin Zang ◽  
Guoguo Sun ◽  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Endothelial Growth Factor

e21741 Background: The skeletal system is one of the most common distant sites of metastatic non-small cell lung cancer (NSCLC) which may lead to skeletal-related events (SREs). Bone metastasis can reduced quality of life. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone metastasis in animal models. Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), which is inhibits tumor angiogenesis. Therefore, we aimed to investigate the efficacy and safety of apatinib plus docetaxel for NSCLC with bone metastases. Methods: Eligible patients of NSCLC with bone metastases who received first-line platinum-based chemotherapy. Treated with apatinib (500 mg, qd, orally) plus docetaxel (60mg/m2, q3w, iv) and zoledronic acid (4mg, q3w, iv). Treatment was continued until disease progression or unacceptable toxic effects. Results: Between July 2017 and June 2019, 10 patients were enrolled. All patients available for efficacy and safety evaluation. the objective response rate (ORR) was 50% and the disease control rate (DCR) was 80%. The median progression-free survival (PFS) was 6.5 months, The proportions of patients with SREs were 20%. The most common Grade 1 or 2 adverse events included hypertension (30%, 3/10), fatigue (30%, 3/10), digestive tract reaction (30%, 3/10), leukopenia (20%, 2/10). Conclusions: Apatinib plus docetaxel prolonged PFS and reduced the incidence of SREs, with acceptable toxic effects. The therapeutic regime may be an option for NSCLC with bone metastases. Clinical trial information: NCT03127319.

Sign in / Sign up

Export Citation Format

Share Document